Pictet Asset Management (Switzerland)’s NovoCure NVCR Stock Holding History

Pictet Asset Management (Switzerland)’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	$1.43M	Sell	34,525 -2,897	-8%	-$180K	﹤0.01%	939
2023 Q1	$2.25M	Sell	37,422 -2,075	-5%	-$166K	﹤0.01%	910
2022 Q4	$2.9M	Sell	39,497 -468	-1%	-$35.2K	﹤0.01%	862
2022 Q3	$3.04M	Buy	39,965 +574	+1%	+$44.8K	﹤0.01%	834
2022 Q2	$2.74M	Buy	39,391 +151	+0.4%	+$11.4K	﹤0.01%	888
2022 Q1	$3.25M	Buy	39,240 +554	+1%	+$40.8K	﹤0.01%	894
2021 Q4	$2.9M	Buy	38,686 +2,837	+8%	+$285K	﹤0.01%	943
2021 Q3	$4.17M	Buy	+35,849	New	+$5.42M	﹤0.01%	876

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Nordwand Advisors Radnor, Pennsylvania $572M AUM 23.09% 1-Year Est. Return

Pictet Asset Management (Switzerland)'s NVCR Position: Q2 2023 in Review

Pictet Asset Management (Switzerland) reduced its NovoCure (NVCR) stake by 7.7% in Q2 2023, selling an estimated $180K and leaving 34,525 shares worth $1.43M. The position accounts for ﹤0.01% of the portfolio, ranked #939.

Pictet Asset Management (Switzerland) first reported a position in NVCR in Q3 2021 and has held it in 8 quarters since. The position peaked at $4.17M in Q3 2021. 268 funds tracked by Wall St. Rank hold NVCR as of Q2 2023.

Pictet Asset Management (Switzerland) held 34,525 shares of NovoCure worth $1.43M as of Q2 2023.
Pictet Asset Management (Switzerland) sold 2,897 NovoCure shares in Q2 2023, an estimated $180K.
NovoCure made up ﹤0.01% of Pictet Asset Management (Switzerland)'s portfolio in Q2 2023, its #939 holding.
Pictet Asset Management (Switzerland) first reported a position in NovoCure in Q3 2021 and has held it in 8 quarters since.
Pictet Asset Management (Switzerland)'s NovoCure position peaked at $4.17M in Q3 2021.
268 funds tracked by Wall St. Rank held NovoCure as of Q2 2023.

Based on Pictet Asset Management (Switzerland)'s 13F filing for Q2 2023, filed 10 Aug 2023.